AstraZeneca’s ZEGFROVY Now Available in the US for EGFR-Mutated NSCLC

AstraZeneca announced US availability of ZEGFROVY (sunvozertinib) for adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations detected by an FDA-approved test.